Showing 1651-1660 of 5771 results for "".
- iTrack Canaloplasty to be Featured at the 2022 ESCRS Annual Meetinghttps://modernod.com/news/itrack-canaloplasty-to-be-featured-at-the-2022-escrs-annual-meeting/2481051/Nova Eye Medical announced that the company’s proprietary canaloplasty technology platform (iTrack™ and iTrack™ Advance) will be featured during the official scientific program of the European Society of Cataract and Refractive Surgeons (ESCRS) 40th Congress on Septemb
- Pixium Vision Announces Participation in Upcoming Scientific Conferences in September 2022https://modernod.com/news/pixium-vision-announces-participation-in-upcoming-scientific-conferences-in-september-2022/2481049/Pixium Vision announced that senior management will participate in the following scientific conferences during September 2022: 22nd EURETINA Congress, September 1-4, Hamburg & Virtual Lloyd Diamond, CEO; Ralf Hornig, PhD, and director of clinic
- Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-24-month-results-showing-increased-effects-over-time-with-pegcetacoplan-in-phase-3-derby-and-oaks-studies-in-geographic-atrophy-ga/2481045/Apellis Pharmaceuticals announced topline data at 24 months showing increased effects over time with intravitreal pegcetacoplan, an investigational, targeted C3 therapy, in the phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Oculis Announces Publication of Phase 2 Data Showing Eye Drop Drug Candidate Relieves Persistent Ocular Discomfort in Severe Dry Eye Diseasehttps://modernod.com/news/oculis-announces-publication-of-phase-2-data-showing-topical-eye-drop-drug-candidate-ocs-02-relieves-persistent-ocular-discomfort-in-severe-dry-eye-disease/2481042/Oculis announced that the results of the double blinded, multicenter and placebo controlled phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe dry eye disease (DED) has been published by the journal C
- Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the Omni Surgical System in Patients with Open Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-long-term-safety-and-effectiveness-data-of-standalone-use-of-the-omni-surgical-system-in-patients-with-open-angle-glaucoma/2481030/Sight Sciences announced 36-month post-surgery follow-up results of the Omni Surgical System. The data demonstrate that the OMNI Surgical System delivers safe, consistent, and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basis, according
- Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-initial-clinical-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481028/Viridian Therapeutics announced positive initial clinical data from the 10mg/kg cohort in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). The double-blind, placebo-controlled phase 1/2 trial is evaluating
- Opthea Announces Financing Deals for OPT-302 in Wet AMDhttps://modernod.com/news/opthea-announces-financing-deals-for-opt-302-in-wet-amd/2481027/Opthea announced two financing deals aimed at advancing OPT-302, a drug candidate for wet age-related macular degeneration (AMD). Opthea announced a nondilutive financing transaction for up to $170 million from investment funds working with Launch Therapeutics to finance and advance the
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Portugalhttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-portugal/2481021/Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement in Portugal for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the pos
- Nova Eye Medical Announces Global Data Registry to Support Role of Canaloplasty for Glaucomahttps://modernod.com/news/nova-eye-medical-announces-global-data-registry-to-support-role-of-canaloplasty-for-glaucoma/2481014/Nova Eye Medical announced the establishment of the iTrack Global Data Registry to collect prospective, multicenter, longitudinal data for canaloplasty in the treatment of glaucoma. A collaboration with the International Glaucoma Surgery Registry (IGSR), the iTrack Global
- Pixium Vision Announces Regulatory Approval of Remote Rehabilitation System for Patients in Clinical Trialshttps://modernod.com/news/pixium-vision-announces-regulatory-approval-of-remote-rehabilitation-system-for-patients-in-clinical-trials/2481010/Pixium Vision announced the approval of the remote rehabilitation system for patients enrolled in the PRIMAvera pivotal trial and the French Feasibility Study in atrophic dry age-related macular degeneration (AMD). The approval was granted by the Ethics Commitee and the Regulatory Autho